SYNTHIA is a pioneering public-private partnership funded by the Innovative Health Initiative (IHI), aiming to revolutionize personalized medicine through the responsible use of synthetic data (SD). The project focuses on developing and validating advanced synthetic data generation (SDG) tools across various data types, including laboratory results, clinical notes, genomics, imaging, and mobile health data.
To demonstrate the utility of synthetic data in diverse medical contexts, SYNTHIA addresses six diseases: lung cancer, breast cancer, multiple myeloma, diffuse large B-cell lymphoma, Alzheimer’s disease, and type 2 diabetes. By generating realistic, multimodal, and longitudinal synthetic datasets, the project seeks to accelerate data-driven solutions of equivalent quality to those derived from real patient data, while ensuring patient privacy.
A key component of SYNTHIA is the development of a federated platform that offers tailored SDG workflows, assessment frameworks for evaluating data privacy, quality, and applicability, and a repository of high-quality synthetic datasets labeled for specific research applications. This platform aims to build trust among stakeholders and promote the responsible use of synthetic data in the health research community.
The SYNTHIA consortium comprises 32 partners from various sectors, including medtech, pharma, academia, medical research, and healthcare institutions. This multidisciplinary collaboration is committed to advancing healthcare applications through synthetic data use, fostering a collaborative environment where innovation can thrive.
Link to EU project website: https://www.ihi-synthia.eu/